TriangleNCT01673646 · OUTCOME
Change in Ring Size From Baseline
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- other - Japanese ring size number
- Interval / dispersion
- Full Range
- Time frame
- Baseline, Months 3, 6, 9, 12
What was measured
Change of clinical signs from baseline: ring size. In Japan, ring sizes are specified using a numerical scale, that only has whole sizes, and does not have simple linear correlation with diameter or circumference. Only numbers are used ranging from 1 to 27. For instance, a ring size of 1 in Japan is equivalent to an inside circumference ring size of 38.86 mm and a ring size of 27 in Japan is equivalent to an inside circumference ring size of 70.15 mm.
Analysis population: FAS: Comprises all patients to whom study treatment has been assigned by randomization. Protocol allowed to change treatment dose (eg, 20mg -\> 40mg -\>20mg -\> 40mg -\>60mg) based on efficacy and safety after 3month treatment. So we combined Arms/groups.
Groups in this outcome
Pasireotide LAR - All Participants
All patients randomized regardless of pasireotide LAR dose.
| Group | Source count |
|---|---|
| Pasireotide LAR - All Participants | 33 |
Reported measurements
Month 3
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pasireotide LAR - All Participants | -1.00 | Not reported | -3.0 | 0.0 | Not reported |
Month 6
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pasireotide LAR - All Participants | -2.00 | Not reported | -6.0 | 2.0 | Not reported |
Month 9
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pasireotide LAR - All Participants | -2.00 | Not reported | -6.0 | 1.0 | Not reported |
Month 12
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pasireotide LAR - All Participants | -2.00 | Not reported | -6.0 | 1.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- -3.0
- upper Limit
- 0.0
- value
- -1.00
- title
- Month 3
- categories
- measurements
- group Id
- OG000
- lower Limit
- -6.0
- upper Limit
- 2.0
- value
- -2.00
- title
- Month 6
- categories
- measurements
- group Id
- OG000
- lower Limit
- -6.0
- upper Limit
- 1.0
- value
- -2.00
- title
- Month 9
- categories
- measurements
- group Id
- OG000
- lower Limit
- -6.0
- upper Limit
- 1.0
- value
- -2.00
- title
- Month 12
- denoms
- counts
- group Id
- OG000
- value
- 33
- units
- Participants
- description
- Change of clinical signs from baseline: ring size. In Japan, ring sizes are specified using a numerical scale, that only has whole sizes, and does not have simple linear correlation with diameter or circumference. Only numbers are used ranging from 1 to 27. For instance, a ring size of 1 in Japan is equivalent to an inside circumference ring size of 38.86 mm and a ring size of 27 in Japan is equivalent to an inside circumference ring size of 70.15 mm.
- dispersion Type
- Full Range
- groups
- description
- All patients randomized regardless of pasireotide LAR dose.
- id
- OG000
- title
- Pasireotide LAR - All Participants
- param Type
- MEDIAN
- population Description
- FAS: Comprises all patients to whom study treatment has been assigned by randomization. Protocol allowed to change treatment dose (eg, 20mg -\> 40mg -\>20mg -\> 40mg -\>60mg) based on efficacy and safety after 3month treatment. So we combined Arms/groups.
- reporting Status
- POSTED
- time Frame
- Baseline, Months 3, 6, 9, 12
- title
- Change in Ring Size From Baseline
- type
- SECONDARY
- unit Of Measure
- other - Japanese ring size number
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice